Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study - TAMI-8

Description:

TAMI-8 was a multicenter, open-label, dose-ranging trial, designed to establish evidence of physiologic activity, as well as to evaluate safety of abciximab among patients receiving recombinant tissue-type plasminogen activator (r-PA) fibrinolysis for ST-segment elevation myocardial infarction (STEMI).